AMT-143 + ropivacaine

AMT-143 + ropivacaine is an investigational, opioid-free, sustained-release local anesthetic formulation developed for post-operative pain management. The product leverages the AmacaGel platform to deliver a known anesthetic—ropivacaine—in a slow-release hydrogel matrix, providing extended localized pain relief at the surgical site. This approach aims to reduce or eliminate the need for opioids in post-surgical pain control, thereby lowering risks of opioid dependency and related side effects. AMT-143 is administered locally via syringe during surgery and has demonstrated sustained anesthetic release up to 14 days in clinical studies. The developer is AmacaThera, which has advanced this combination into Phase 1 clinical trials for postoperative pain[1][2][3][4][5].